Purpose: To examine the difference in patient's pain experience in the setting of intravitreal anti-VEGF injections with pretreatment of topical ice-therapy compared with no-ice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
42
Ice therapy will be provided prior to intravitreal injection provision
No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
University of Minnesota
Minneapolis, Minnesota, United States
Discomfort assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to discomfort, while a rating of ten signifies the maximum self-reported subjective rating attributed to discomfort.
Time frame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Itching assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to itching, while a rating of ten signifies the maximum self-reported subjective rating attributed to itching.
Time frame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Burning assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to burning, while a rating of ten signifies the maximum self-reported subjective rating attributed to burning.
Time frame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Overall Pain assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall pain, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall pain.
Time frame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Overall Tolerability assessed by the visual analog scale
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall tolerability, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall tolerability.
Time frame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Discomfort assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to discomfort, while a rating of ten signifies the maximum self-reported subjective rating attributed to discomfort.
Time frame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
Itching assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to itching, while a rating of ten signifies the maximum self-reported subjective rating attributed to itching.
Time frame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
Burning assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to burning, while a rating of ten signifies the maximum self-reported subjective rating attributed to burning.
Time frame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
Overall Pain assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall pain, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall pain.
Time frame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
Overall Tolerability assessed by the visual analog scale
This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall tolerability, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall tolerability.
Time frame: This will be assessed at 24-hours after the conclusion of the intravitreal injection